Sungja Cho

Sungja Cho

Auto-generated profile, based on publicly available information

Sungja Cho

Neudive Inc, Daegu, Republic of Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
MKMoon Jung Kim
Moon Jung Kim
IPInho Park
Inho Park
MLMyung Ho Lim
Myung Ho Lim
KPKi Chung Paik
Ki Chung Paik
SCSungja Cho
Sungja Cho
MHMina Ha
Mina Ha
Kim MJ, et al. J Korean Med Sci. 2017 Mar;32(3):401-406. https://doi.org/10.3346/jkms.2017.32.3.401

9 September 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
ELEnn Young Lee
Enn Young Lee
SCSungJa Cho
SungJa Cho
RJRan Ju
Ran Ju
HKHyunjae Kim
Hyunjae Kim
TCTae Young Choi
Tae Young Choi
YJYoo-Sook Joung
Yoo-Sook Joung
Background: Autism spectrum disorder (ASD) and social communication disorder (SCD) are neurodevelopmental disorders characterized by deficits in social communication that hinder social adaptation, with limited pharmacological options for therapy owing to the absence of identified biomarkers. Individuals with ASD or SCD require lifelong interventions tailored to their development stages. However, most existing interventions primarily focus on early childhood, leaving adolescents relatively underserved. Moreover, timely access to interventions is often limited by geographic and economic barriers as specialized clinics and therapists tend to be concentrated in major urban areas. Objective: This pilot randomized clinical trial aimed to evaluate the initial safety and efficacy of NDTx-01, a digital therapeutic (DTx) for adolescents with ASD or SCD. NDTx-01 was designed to overcome the accessibility limitations by integrating cognitive behavioral therapy principles, story-based interventions, and gamification elements. Methods: We introduce a protocol for a multicenter, prospective, assessor-blinded pilot randomized clinical trial involving children and adolescents aged 10 to 18 years diagnosed with ASD or SCD. Participant enrollment was conducted at 3 major medical hospitals. Enrolled participants were randomly assigned to either the intervention group (NDTx-01 and treatment as usual [TAU]) or the control group (TAU only). TAU included medications and therapeutic services. Participants were instructed to use the app approximately 10 minutes per day, 5 days a week. To evaluate the efficacy of NDTx-01, standardized tools were administered, including the Korean version of the Vineland Adaptive Behavior Scales, Second Edition (K-VABS-II); the Social Responsiveness Scale, Second Edition; Clinical Global Impressions–Severity (CGI-S); Clinical Global Impressions–Improvement (CGI-I); the Social Communication Questionnaire; and the Korean version of the Stress Index for Parents of Adolescents. Assessments were conducted in weeks 0, 1, 2, 4, and 6, except for K-VABS-II, CGI-S, and CGI-I, which were administered only in weeks 0, 4, and 6. Statistical analyses were conducted using the SAS software. Between-group differences were assessed using independent 2-tailed 2-sample t tests or Wilcoxon rank sum tests. Within-group changes were evaluated using paired t tests or Wilcoxon signed rank tests. Results: From August 2024 to December 2024, a total of 42 individuals were screened, 39 (93%) participants who met the inclusion criteria were enrolled, and 1 participant withdrew consent; the remaining participants completed the study. The pilot randomized clinical trial was successfully completed, and the results were published in April 2025. As of 2025, we are conducting a confirmatory clinical trial at 5 major hospitals across South Korea. Conclusions: The results of this pilot clinical trial provided important insights into the initial safety and efficacy of DTx as interventions for adolescents with ASD and SCD. Both groups demonstrated statistically significant improvements in adaptive skills and socialization. Trial Registration: Clinical Research Information Service KCT0009140; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=26713 International Registered Report Identifier (IRRID): DERR1-10.2196/66419

14 September 2024 in JMIR Preprints
Verified
Preprint
Open access
YJYoo-Sook Joung
Yoo-Sook Joung
ELEnn Young Lee
Enn Young Lee
SCSung Ja Cho
Sung Ja Cho
RJRan Ju
Ran Ju
HKHyun Jae Kim
Hyun Jae Kim
JYJae Hyun Yoo
Jae Hyun Yoo
BACKGROUND Autism spectrum disorder (ASD) and social communication disorder (SCD) are characterized by deficits in social communication that hinder social adaptation, with limited pharmacologic options for therapy due to the absence of identified biomarkers. OBJECTIVE Recognizing the need for accessible and cost-effective interventions, we developed the digital therapeutic NDTx-01, integrating cognitive behavioral therapy principles, story-based interventions, and gamification elements. METHODS This study introduces a protocol for evaluating the efficacy and safety of NDTx-01 through a multicenter, prospective, randomized, assessor-blinded pilot trial involving adolescents aged 1018 years. Participant recruitment and enrollment will be executed in three major medical hospitals, where inter-reliability will be managed by the study team. Enrolled participants, divided into intervention and control groups, will undergo a 6-week intervention with NDTx-01 and usual care or maintain usual care, respectively. The intervention, implemented by NDTx-01, will be structured to last for 6 weeks, with sessions of approximately 10 minutes daily, 5 days a week. Following this, data analysis, including frequency analysis, descriptive statistical analysis, and tests for within-group and between-group differences, will be undertaken. RESULTS As of August 2024, we enrolled 39 patients, and this clinical trial has been successfully completed. CONCLUSIONS Anticipated results, to be published in April 2024, aim to contribute crucial insights into the effectiveness of digital therapeutics as interventions for ASD and SCD in adolescents.

23 September 2026 in JMIR Serious Games
Verified
Journal Article
Open access
MJMinyoung Jung
Minyoung Jung
JRJu Ran
Ju Ran
ELEnnyoung Lee
Ennyoung Lee
YSYoungkyung Sunwoo
Youngkyung Sunwoo
SKSooYeon Kim
SooYeon Kim
SCSungja Cho
Sungja Cho
Background: Distinguishing autism spectrum disorder (ASD) from social communication disorder (SCD) is clinically challenging because both conditions present with overlapping social communication deficits. Standard caregiver-reported instruments capture surface-level behavioral similarities rather than underlying cognitive differences, motivating the development of digital gamified assessments that measure social cognitive processes directly. Objective: This study developed and evaluated a 2-stage gamified digital pipeline: stage 1 (Buddy Plan, a self-report module) for high-sensitivity ASD screening, and stage 2 (Buddy Drill, story-based social-judgment scenarios), which was examined with a leakage-controlled analysis, for assessing whether ASD can be differentiated from SCD. Methods: In this cross-sectional diagnostic accuracy study, 275 children and adolescents aged 6‐18 years (mean 11.07, SD 3.13 years; 175/275, 63.6% male) were recruited by convenience sampling from 5 clinical and community sites in the Republic of Korea (May 2024 to February 2025) across 5 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) groups: ASD (n=51), SCD (n=54), attention-deficit/hyperactivity disorder (n=23), high risk (n=52), and neurotypically developing (ND; n=95). Diagnoses were established by board-certified child psychiatrists. Participants completed 2 tablet-based modules: Buddy Plan (52 self-report items; stage 1) and Buddy Drill (153 story-based scenarios; stage 2). The primary outcome was diagnostic accuracy (area under the receiver operating characteristic curve [AUC], sensitivity, and specificity). Four machine learning algorithms were trained with nested cross-validation (5×5 folds). For stage 2, item selection and imputation were performed within each training fold. Explainability used Shapley Additive Explanations (SHAP). Significance was set at α=.05 (2-sided) with bootstrap 95% CIs. Results: Group differences were tested by 1-way ANOVA. For stage 1 (ASD vs ND; n=146), random forest achieved a nested AUC of 0.912 (95% CI 0.856‐0.953). At a threshold of 0.200, sensitivity was 96.1% (49/51; 95% CI 86.8%‐99.5%) and specificity was 58.9% (56/95; 95% CI 48.4%‐68.9%), with 2 false negatives. For stage 2 (ASD vs SCD; n=100), the fully nested pipeline yielded only chance-level discrimination: regularized logistic regression achieved a nested AUC of 0.62 (95% CI 0.51‐0.74), and no feature configuration (self-report: 0.55, objective: 0.62, combined: 0.63) exceeded chance. SHAP identified 5 cross-algorithm stage 1 biomarkers with significant ASD-versus-ND differences (all P <.01) and no evidence of sex bias. Conclusions: The gamified Buddy Plan module shows promise for high-sensitivity ASD screening. In contrast, once feature-selection leakage was removed with a fully nested pipeline, the Buddy Drill module did not robustly differentiate ASD from SCD, and the apparent advantage of objective features over self-report features seen in leaky analyses did not persist. Because the results derive from internal cross-validation in a single, predominantly male Korean cohort without external validation or IQ matching, they represent preliminary evidence of screening feasibility rather than validated clinical differentiation. Prospective, externally validated, IQ- and language-matched studies are required.

23 February 2026 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Open access
PDF file
JPJeong-Hyeon Park
Jeong-Hyeon Park
SKSeong-Jung Kim
Seong-Jung Kim
SCSung Ja Cho
Sung Ja Cho
SKSun-Hong Kwon
Sun-Hong Kwon
DKDong-Won Kang
Dong-Won Kang
Eui-Kyung LeeEui-Kyung Lee
Eui-Kyung Lee
Objective This study examined age-specific utilization patterns and costs of developmental rehabilitation therapy among children with autism spectrum disorder (ASD) in South Korea. Methods A cross-sectional online survey was conducted in November 2024 among caregivers of children under 18 years with ASD. Participants were recruited via online communities for caregivers of children with ASD. Quota sampling was employed to categorize respondents into four age groups (≤ 6, 7–9, 10–12, and ≥ 13 years) based on school age. Only those whose children had received developmental rehabilitation therapy within the past three months were included. Therapy type, frequency, and monthly costs were assessed. Generalized linear models with a gamma distribution were used to identify factors associated with total and out-of-pocket costs. Results Data from 144 children with ASD were analyzed. Children aged 7–12 received the widest range of therapies, whereas adolescents ≥ 13 years received the fewest. Applied Behavior Analysis, the costliest therapy, was most frequently used among children ≤ 6 years. This youngest group also incurred the highest monthly costs (total: US$682.6; out-of-pocket: US$557.7), despite the lowest proportion of government voucher support (7.1%). Younger age and greater disability severity were associated with higher expenditures. Financial burden was the most common reason for planned therapy discontinuation. Conclusion Developmental rehabilitation therapy for ASD shows marked age-related differences in utilization and financial burden. Younger children, particularly those ≤ 6 years, receive more intensive and costly therapies but have the lowest public support. Targeted policy interventions are needed to improve access and reduce the financial burden across age groups.